German Pharmaceutical Law Removes Incentives For Orphan Drug R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
National biotechnology and pharmaceutical industry associations object to certain provisions in the proposed German law on restructuring the pharma sector, AMNOG, that would add health technology assessments for orphan drugs.
You may also be interested in...
Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.
Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.
New German Reimbursement Process Splits Opinion Ahead Of First Assessments
Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.